<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358497</url>
  </required_header>
  <id_info>
    <org_study_id>TR001</org_study_id>
    <nct_id>NCT04358497</nct_id>
  </id_info>
  <brief_title>Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome</brief_title>
  <acronym>ENDPCS</acronym>
  <official_title>Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clínicas Dr. Manuel Quintela</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Republic, Uruguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Cardiovascular Universitario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalario Pereyra Rossell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clínicas Dr. Manuel Quintela</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy and safety of endovascular treatment with sandwich technique (controlled
      release coils and 2% polidocanol foam) associated with diosmin-hisperidine and ibuprofen
      medical treatment and only the best chronic medical treatment available diosmin-hisperidine
      and ibuprofen for 3 months, in women of active gynecological age carrying pelvic congestion
      syndrome in public assistance in Montevideo, Uruguay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic congestion syndrome (PCS) is a recognized and frequent cause of Chronic Pelvic Pain
      (10% to 30%). It is defined as the presence of chronic symptoms, which may include pelvic
      pain, perineal heaviness, urinary urgency and postcoital pain, caused by reflux and / or
      obstruction of the gonadic and / or pelvic veins, and that may be associated with vulvar,
      perineal and lower limbs varicose veins.

      There is no standard approach to managing PCS. According to expert recommendations, therapies
      should be individualized according to the patient's symptoms and needs.

      Medical treatment options include progestagens, danazol, combined oral hormonal
      contraceptives, phlebotonics such as hisperidine-added diosmin, non-steroidal
      anti-inflammatory drugs and gonadotropin-releasing hormone (GnRH) agonists

      Currently, the only accepted chronic medical treatment is the association of non-steroidal
      and phlebotonic anti-inflammatories, but they have shown a poor symptomatic benefit in
      reducing pain.

      Surgical treatment has evolved over time mainly in the hands of laparoscopic techniques,
      currently the endovascular option is the most widely accepted for presenting excellent
      long-term results with abolition of pain in up to 90% at 2 years.

      HYPOTHESIS

      Endovascular treatment of pelvic congestion syndrome is better in terms of pain control and
      quality of life compared to drug treatment.

      General objective

      Compare the efficacy and safety of endovascular treatment with sandwich technique (controlled
      release coils and 2% polidocanol foam) associated with diosmin-hisperidine and ibuprofen
      medical treatment and only the best chronic medical treatment available diosmin-hisperidine
      and ibuprofen for 3 months, in women of active gynecological age carrying pelvic congestion
      syndrome in public assistance in Montevideo, Uruguay.

      Specific objectives

      • Compare pain in patients undergoing endovascular treatment with the best

      medical treatment.

        -  Evaluate the persistence of pelvic varices in patients undergoing endovascular treatment
           of SCP.

        -  Compare the Female Sexual Satisfaction Index in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Blind randomized clinical trial designed to compare the efficacy and safety of endovascular treatment of Pelvic congestion syndrome.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Phlebography will be performed to both groups. On the experimental group, the treatment of the pelvic congestion will be performed, while the procedure will be stopped on the control group. Neither the patient or the reference gynecologist will be informed if the treatment took place.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>30 days</time_frame>
    <description>Pain assessment 1-10 from no pain to severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>3 months</time_frame>
    <description>Pain assessment 1-10 from no pain to severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lattinen index</measure>
    <time_frame>30 days</time_frame>
    <description>chronic pain assessment 2-22 from low to high</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lattinen index</measure>
    <time_frame>3 months</time_frame>
    <description>chronic pain assessment 2-22 from low to high</description>
  </primary_outcome>
  <primary_outcome>
    <measure>McGill Pain Questionnaire</measure>
    <time_frame>30 days</time_frame>
    <description>subjective pain experience assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>McGill Pain Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>subjective pain experience assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Female sexual function index</measure>
    <time_frame>30 days</time_frame>
    <description>questionnaire that assesses different domains of sexual function. 0-48 from no sexual distress to high level of sexual distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female sexual function index</measure>
    <time_frame>3 months</time_frame>
    <description>questionnaire that assesses different domains of sexual function. . 0-48 from no sexual distress to high level of sexual distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>varicose and reflux persistance by transabdominal duplex scan</measure>
    <time_frame>30 days</time_frame>
    <description>transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>varicose and reflux persistance by transabdominal duplex scan</measure>
    <time_frame>3 months</time_frame>
    <description>transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>varicose and reflux persistance by transvaginal duplex scan</measure>
    <time_frame>3 months</time_frame>
    <description>transabdominal duplex scan: varicose permeability, prescience of gonadic or iliac reflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>varicose persistance assesment by tomography</measure>
    <time_frame>3 months</time_frame>
    <description>angiotomography: Varicose and conadic Patency</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Deep venous thrombosis by duplex ultrasound</measure>
    <time_frame>30 days</time_frame>
    <description>Deep venous thrombosis of the iliac or femoral axis will be reported</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pelvic Congestive Syndrome</condition>
  <condition>Pelvic Varices</condition>
  <condition>Venous Disease</condition>
  <arm_group>
    <arm_group_label>Interventional treatment plus best chronic medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best chronic medical treatment alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic® Concerto® detachable coil system</intervention_name>
    <description>coil embolization of the reflux pathways</description>
    <arm_group_label>Interventional treatment plus best chronic medical treatment</arm_group_label>
    <other_name>concerto detachable coil system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sclerosis</intervention_name>
    <description>Pelvic varices sclerosis with polidocanol foam</description>
    <arm_group_label>Interventional treatment plus best chronic medical treatment</arm_group_label>
    <other_name>Foam sclerosis with polidocanol 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin / Hesperidin</intervention_name>
    <description>Best chronic medial treatment</description>
    <arm_group_label>Best chronic medical treatment alone</arm_group_label>
    <arm_group_label>Interventional treatment plus best chronic medical treatment</arm_group_label>
    <other_name>daflon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg</intervention_name>
    <description>NSAID treatment</description>
    <arm_group_label>Best chronic medical treatment alone</arm_group_label>
    <arm_group_label>Interventional treatment plus best chronic medical treatment</arm_group_label>
    <other_name>Nsaid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active gynecological age

          -  Chronic pelvic pain diagnosed by gynecologist of at least 6 months of evolution.

          -  Transvaginal duplex ultrasound: presence of periuterine varicose veins defined by
             veins larger than 5mm in diameter with reflux greater than 0.5 seconds on Valsava
             maneuvers.

        Exclusion Criteria:

          -  Presence of other causes of chronic pelvic pain: endometriosis, pelvic inflammatory
             disease, postoperative adhesions, uterine myoma, adenomyosis, ovarian tumors,
             polycystic ovary.

          -  Fibromyalgia

          -  BMI greater than 35

          -  Chronic kidney disease

          -  thrombophilia

          -  Alterationof coagulation.

          -  Allergy to iodinated contrast medium.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Sarutte, VS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiovascular Universitario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Sarutte, VS</last_name>
    <phone>+59899533449</phone>
    <email>ssarutte1@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauricio Volpi, VS</last_name>
    <phone>+59899605556</phone>
    <email>mavolpi@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clínicas Dr. Manuel Quintela</investigator_affiliation>
    <investigator_full_name>Eduardo Sebastian Sarutte Rosello, MD VS MSc</investigator_full_name>
    <investigator_title>Vascular Surgery Asistant Professor</investigator_title>
  </responsible_party>
  <keyword>pelvic congestion syndrome</keyword>
  <keyword>sclerosis</keyword>
  <keyword>coil embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data base for all variables will be available for researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From April 2022 to april 2024</ipd_time_frame>
    <ipd_access_criteria>Data will be shared on request, after signing a discretion agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

